🇺🇸 FDA
Pipeline program

ASP8825

8825-CL-0005

Phase 3 small_molecule completed

Quick answer

ASP8825 for Restless Legs Syndrome is a Phase 3 program (small_molecule) at Astellas Pharma Inc with 1 ClinicalTrials.gov record(s).

Program details

Company
Astellas Pharma Inc
Indication
Restless Legs Syndrome
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials